GlassScriptPhysician profile
Celeste G Woolum
NPI 1548517477
$871.99
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $843 · 2022: $28.91.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $143.47 | 2021 | |
| Novo Nordisk INC | $132.78 | 2021 | |
| Janssen Pharmaceuticals, INC | $112.48 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.95 | 2021 | |
| Avanir Pharmaceuticals, INC. | $69.92 | 2021 | |
| Lilly USA, LLC | $54.42 | 2021 | |
| Abbvie INC. | $51.54 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $49.91 | 2021 | |
| Astellas Pharma US INC | $49.32 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.28 | 2021 | |
| Esperion Therapeutics, INC. | $43.78 | 2021 | |
| Eisai INC. | $17.35 | 2021 | |
| Merck Sharp & Dohme LLC | $15.21 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.58 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Woolum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.